Lytton, foundation report 5% Xtant Medical (NASDAQ: XTNT) stake

Rhea-AI Filing Summary

Laurence W. Lytton and the Lytton-Kambara Foundation report significant holdings of Xtant Medical Holdings, Inc. common stock on an amended Schedule 13G. Lytton is deemed to beneficially own 7,702,002 shares, or 5.5% of the class, while the foundation holds 7,026,104 shares, or 5.0%.

Lytton has sole voting and dispositive power over 675,898 shares and shared voting and dispositive power over 7,026,104 shares through the foundation. The percentages are calculated based on 140,004,240 shares outstanding as of November 7, 2025. The filing certifies the securities are not held to change or influence control.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 12:57 PM Learn about SEC filing dates

FAQ

What ownership stake in XTNT does Laurence W. Lytton report?

Lytton reports beneficial ownership of 7,702,002 XTNT common shares, representing 5.5% of the class. This includes 675,898 shares over which he has sole voting and dispositive power, and 7,026,104 shares over which he shares voting and dispositive power.

How many XTNT shares does the Lytton-Kambara Foundation hold?

The Lytton-Kambara Foundation reports beneficial ownership of 7,026,104 XTNT common shares, equal to 5.0% of the class. The foundation has shared voting and shared dispositive power over all of these shares and no sole voting or dispositive authority.

What share count did the XTNT Schedule 13G/A use for its ownership percentages?

The ownership percentages are calculated using 140,004,240 XTNT common shares outstanding as of November 7, 2025. This outstanding share figure comes from Xtant Medical’s Form 10-Q for the quarterly period ended September 30, 2025.

Does the XTNT Schedule 13G/A indicate an attempt to influence control?

The filing states the securities were not acquired and are not held for the purpose of changing or influencing control of Xtant Medical. It also notes they are not held in connection with any transaction having that purpose, aside from certain nomination-related activities.

What type of SEC filing did XTNT’s shareholders submit here?

This is an amended Schedule 13G reporting beneficial ownership of Xtant Medical common stock. It is a disclosure of holdings by Laurence W. Lytton and the Lytton-Kambara Foundation, not a registration of new securities or an earnings announcement.

Who signed the XTNT Schedule 13G/A filing and in what capacities?

Laurence W. Lytton signed twice on February 17, 2026: once as the individual reporting person and once as President, in connection with the Lytton-Kambara Foundation, confirming the accuracy of the ownership information disclosed.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Xtant Medical Holdings, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

98420P308

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 98420P308

1

Names of Reporting Persons

LYTTON LAURENCE W

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 675,898.00
6	Shared Voting Power 7,026,104.00
7	Sole Dispositive Power 675,898.00
8	Shared Dispositive Power 7,026,104.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

7,702,002.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.5 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: Percentage calculated based on 140,004,240 shares of Common Stock outstanding on November 7, 2025, as reported in the Form 10-Q filed by the Issuer for the quarterly period ended September 30, 2025.

SCHEDULE 13G

CUSIP No. 98420P308

1

Names of Reporting Persons

LYTTON-KAMBARA FOUNDATION

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 7,026,104.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 7,026,104.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

7,026,104.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.0 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: Percentage calculated based on 140,004,240 shares of Common Stock outstanding on November 7, 2025, as reported in the Form 10-Q filed by the Issuer for the quarterly period ended September 30, 2025.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Xtant Medical Holdings, Inc.
(b)	Address of issuer's principal executive offices: 664 Cruiser Lane, Belgrade, MT 59714
Item 2.
(a)	Name of person filing: Laurence W. Lytton Lytton-Kambara Foundation
(b)	Address or principal business office or, if none, residence: 467 Central Park West New York, NY 10025
(c)	Citizenship: USA
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 98420P308
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Lytton: 7,702,002 Foundation: 7,026,104
(b)	Percent of class: Lytton: 5.5% Foundation: 5.0%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Lytton: 675,898 Foundation: 0
	(ii) Shared power to vote or to direct the vote: Lytton: 7,026,104 Foundation: 7,026,104
	(iii) Sole power to dispose or to direct the disposition of: Lytton: 675,898 Foundation: 0
	(iv) Shared power to dispose or to direct the disposition of: Lytton: 7,026,104 Foundation: 7,026,104
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

LYTTON LAURENCE W

Signature:	/s/ Laurence W. Lytton
Name/Title:	Reporting Person
Date:	02/17/2026

LYTTON-KAMBARA FOUNDATION

Signature:	/s/ Laurence W. Lytton
Name/Title:	President
Date:	02/17/2026

Exhibit Information

EXHIBIT 99.1 - AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G